What is the most effective β3‑adrenergic agonist for a male patient with bothersome urinary urgency and a negative infection work‑up?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Best β3-Agonist for Male Patient with Urinary Urgency

For a male patient with bothersome urinary urgency and negative infection work-up, mirabegron is the β3-agonist of choice, as it is currently the only FDA-approved β3-adrenergic agonist available for overactive bladder treatment. 1

Primary Recommendation

The 2024 AUA/SUFU guidelines explicitly recommend offering β3-agonists to patients with OAB to improve urinary urgency, frequency, and urgency urinary incontinence 1. Importantly, the guidelines state that a trial of β3-agonists is typically preferred before antimuscarinic medications 1, making this the first-line pharmacologic choice for your patient.

Why Mirabegron Specifically

While vibegron is another β3-agonist that has shown promise in recent research, mirabegron remains the established option with:

  • Extensive clinical trial data demonstrating efficacy in reducing micturition frequency, incontinence episodes, urgency, and improving voided volume and quality of life over 12-52 weeks 2
  • Favorable tolerability profile with significantly lower rates of dry mouth compared to antimuscarinics 2
  • Real-world evidence supporting better persistence and adherence compared to antimuscarinics 2

Dosing Approach

Start with mirabegron 25 mg daily, with option to increase to 50 mg daily based on response and tolerability. The 50 mg dose has demonstrated superior efficacy in reducing micturition frequency 3.

Special Considerations for Male Patients

Important caveat: Data in male OAB patients are somewhat variable 2. However, recent 2026 evidence specifically in males with persistent lower urinary tract symptoms showed mirabegron achieved:

  • 78.8% overall clinical benefit (≥50% improvement)
  • 51% reduction in nocturia
  • 48% reduction in urgency
  • 58% improvement in quality of life
  • 90.9% treatment persistence 4

If Monotherapy Fails

Consider combination therapy with mirabegron plus an antimuscarinic (specifically solifenacin 5 mg + mirabegron 50 mg has the strongest evidence from SYNERGY and BESIDE trials) 5. This combination shows improved efficacy without significant safety concerns, though it increases risk of dry mouth and constipation 3.

Key Advantages Over Antimuscarinics

  • No dementia risk: Unlike antimuscarinics, which have documented associations with incident dementia that may be cumulative and dose-dependent 1
  • No contraindications in narrow-angle glaucoma, impaired gastric emptying, or urinary retention history 1
  • Better tolerability leading to improved real-world adherence 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.